Rezolute (NASDAQ:RZLT) Issues Earnings Results

Rezolute (NASDAQ:RZLT) issued its quarterly earnings data on Thursday. The company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.30) by ($0.14), Zacks reports.

Rezolute Stock Up 2.1 %

Rezolute stock traded up $0.10 during trading on Friday, hitting $4.92. The stock had a trading volume of 125,382 shares, compared to its average volume of 432,587. The stock’s 50 day moving average is $4.61 and its two-hundred day moving average is $3.69. Rezolute has a 1 year low of $0.72 and a 1 year high of $6.10. The stock has a market cap of $197.46 million, a price-to-earnings ratio of -4.45 and a beta of 1.18.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on RZLT. Maxim Group raised their price objective on Rezolute from $8.00 to $10.00 and gave the company a “buy” rating in a research note on Tuesday, August 6th. HC Wainwright restated a “buy” rating and set a $14.00 price target on shares of Rezolute in a report on Monday, September 9th. BTIG Research increased their price objective on shares of Rezolute from $13.00 to $15.00 and gave the company a “buy” rating in a research note on Tuesday, September 10th. Guggenheim assumed coverage on Rezolute in a research note on Tuesday, August 27th. They issued a “buy” rating and a $11.00 target price on the stock. Finally, Craig Hallum started coverage on Rezolute in a report on Tuesday, June 4th. They issued a “buy” rating and a $14.00 target price for the company. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $11.57.

Rezolute Company Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.